Retatrutide cuts weight 25% at 12 mg in Lilly phase 3
The 18-month trial in 2,339 adults with obesity and no diabetes included participants with knee osteoarthritis and obstructive sleep apnea.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 14 13:33 ETSource: Newsweek
The wire
- 01Published September 29, the Eli Lilly-funded phase 3 reported average weight reductions of 17.6% at 4 mg, 23.7% at 9 mg and 25% at 12 mg, versus 3.9% on placebo.
- 02Retatrutide targets GIP and glucagon receptors in addition to GLP-1; the added glucagon activity is thought to raise energy expenditure beyond what semaglutide-class drugs deliver.
- 03Yale endocrinologist Brian Wojeck calls it the most effective agent in a published trial but notes many other drugs are in study; no approval date is given.
From the source
Read at newsweek.comWhat Is Retatrutide and When Could Weight-Loss Drug Be Publicly Available?
A phase 3 clinical trial for a new weight-loss drug funded by Eli Lilly found that using retatrutide "resulted in significant weight reduction," as well as other improvements among participants.
